Factor xa inhibitor antidote

Andexanet is the first compound being studied as an antidote for factor Xa inhibitors that directly and specifically.Portola Pharmaceuticals Announces Investigational Universal Factor Xa Inhibitor Antidote Reverses Anticoagulant Activity of Factor Xa Inhibitors.

Unit dose formulation of antidotes for factor xa

Revisions include 322 more changes than CMS proposed in April.

Portola Announces Oral Presentation of Phase 2 Data on

ESC 2011 — PARIS — Oral direct factor Xa inhibitors are an emerging class of drugs that are poised take much of the market from warfarin on a wave of enthusiasm.

New antidote for factor Xa inhibitors | K.G. Jebsen TREC

For ethical reasons, this multicenter, prospective study is not randomized, and all participants receive andexanet alfa given as a bolus dose over 30 minutes followed by a two-hour infusion.Additional information is available in this support article.To date, the ANNEXA-4 trial has enrolled more than 130 of the approximately 270 patients targeted for inclusion.

Antidote reverses anticoagulant effects of factor Xa

BackgroundBleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the reversal of the effects of these drugs.

Andexanet alfa is a recombinant factor Xa molecule that binds to and sequesters factor Xa inhibitors in the blood, making them unavailable to bind to native factor Xa.Portola Announces Phase 3 ANNEXA-R Study of Andexanet Alfa and Factor Xa Inhibitor XARELTO(R) (rivaroxaban) Met Primary Endpoint With High Statistical Significance.A recombinant protein specifically designed to reverse the anticoagulant activity of both direct and indirect Factor Xa inhibitors.After completing the CAPTCHA below, you will immediately regain access to.The company plans to meet with the FDA as soon as possible to resolve the outstanding questions in the CRL and to determine appropriate next steps.The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa.Bristol-Myers Squibb (BMS), Pfizer, and Portola Pharmaceuticals said they will conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa.

Andexanet as an Antidote for Oral Anti-Factor Xa

Portola Announces Phase 3 ANNEXA-R Study of Andexanet Alfa

Portola Inks Deals for Factor Xa Antidote with BMS, Pfizer

The FDA has issued a Complete Response Letter to Portola Pharmaceuticals for its orphan drug Andexxa (andexanet alfa).After the bolus dose, median anti-factor Xa activity was reduced by 89% from baseline for patients receiving rivaroxaban and by 93% for treated with apixaban and was sustained at similar levels for the duration of the two-hour infusion.

Initiates Phase 4 Study To Support Accelerated Approval Of Andexanet Alfa -- Its Breakthrough-Designated Factor Xa Inhibitor Antidote.

A rapid and effective antidote for anticoagulant bleeds

C-Suite Survey: Health Care Leaders Use Generics, Tighter Formularies, Physician Education to Control Drug Spending.

Portola Pharmaceuticals Announces Validation Of Marketing

Andexanet alfa achieved primary, secondary efficacy

Andexanet alfa reduced anticoagulant activity by roughly 90% within half an hour among patients with acute major bleeding while receiving a factor Xa (fXa) inhibitor.

The efficacy population included only the 47 patients whose bleed severity met the specific inclusion criteria, as determined by an IAC, and whose baseline anti-factor Xa activity was substantially elevated.Universal, class-specific and drug-specific reversal agents for.Beyond the pills: Accountable Health Communities highlight social comorbidities that affect our health.Andexanet alfa was associated with the normalization of blood clotting and the cessation of bleeding.Direct inhibitors of factor Xa (fXa) — such as rivaroxaban — are a new class of anticoagulants but lack effective antidotes.Factor Xa Inhibitor Rivaroxaban.